- Home
- TGTX vs PNFP Comparison
TGTX vs PNFP Comparison
Compare TGTX & PNFP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- PNFP
- Stock Information
- Founded
- TGTX 1993
- PNFP 2000
- Country
- TGTX United States
- PNFP United States
- Employees
- TGTX N/A
- PNFP N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- PNFP Major Banks
- Sector
- TGTX Health Care
- PNFP Finance
- Exchange
- TGTX Nasdaq
- PNFP Nasdaq
- Market Cap
- TGTX 5.5B
- PNFP 6.6B
- IPO Year
- TGTX 1995
- PNFP N/A
- Fundamental
- Price
- TGTX $32.18
- PNFP $86.27
- Analyst Decision
- TGTX Strong Buy
- PNFP Buy
- Analyst Count
- TGTX 5
- PNFP 14
- Target Price
- TGTX $48.20
- PNFP $112.23
- AVG Volume (30 Days)
- TGTX 1.8M
- PNFP 1.2M
- Earning Date
- TGTX 11-03-2025
- PNFP 10-15-2025
- Dividend Yield
- TGTX N/A
- PNFP 1.12%
- EPS Growth
- TGTX N/A
- PNFP 49.26
- EPS
- TGTX 2.78
- PNFP 7.83
- Revenue
- TGTX $531,898,000.00
- PNFP $1,885,186,000.00
- Revenue This Year
- TGTX $82.31
- PNFP $31.11
- Revenue Next Year
- TGTX $49.05
- PNFP $119.44
- P/E Ratio
- TGTX $11.61
- PNFP $10.98
- Revenue Growth
- TGTX 100.88
- PNFP 21.58
- 52 Week Low
- TGTX $25.28
- PNFP $81.57
- 52 Week High
- TGTX $46.48
- PNFP $131.91
- Technical
- Relative Strength Index (RSI)
- TGTX 39.20
- PNFP 42.09
- Support Level
- TGTX $31.07
- PNFP $83.60
- Resistance Level
- TGTX $34.74
- PNFP $87.38
- Average True Range (ATR)
- TGTX 1.70
- PNFP 1.93
- MACD
- TGTX -0.27
- PNFP 0.23
- Stochastic Oscillator
- TGTX 17.74
- PNFP 42.16
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About PNFP Pinnacle Financial Partners Inc.
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. It operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.